Pursuant to Regulation 30, read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), including any amendments thereto, Hester Biosciences has informed that the Board of Directors by circulation of resolution, and on the recommendations of the Nomination and Remuneration Committee and Audit Committee of the Board, has approved the appointment of Ashish Desai as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company (categorised as Senior Management Personnel), presently serving as Group Finance Controller will assume the role of Chief Financial Officer of the Company with effect from 20 November 2025. The brief details of the aforesaid appointment as prescribed under SEBI Listing Regulations read with No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13 July 2023, is enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: